Inscripta
Boulder, US · Delaware corporation · 10 known investors
Founders & leadership
MG
Michael GraigeExecutive
RM
Ron McGrathExecutive
SK
Sri KosarajuExecutive
DL
Dianna L. DeVoreExecutive
Board
RW
BR
Bryan RobertsBoard director
JR
John R. StuelpnagelBoard director
Investors · 10
Foresite CapitalWest Hollywood
iGlobe PartnersSingapore · $600K – $6M
KorysHalle · $5.4M
Oak HC/FTStamford
OMX VenturesLincolnshire
Paladin Capital GroupWashington · $100K – $5M
Spruce Capital PartnersSouth San Franciscovia Roger Wyse · board
VenrockPalo Alto · $500K – $10M
Vertical Venture PartnersPalo Alto · $500K – $4M
+ND CapitalreportedWoodside · $540K – $5.4M
Reported raises · per SEC filings
Form D private placements$473.9M disclosed across 14 rounds · 2016–2022
▶$1.9MraisedJun 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Roger WyseDirector
- Kristala L. Jones PratherDirector
- Sri KosarajuExecutive Officer, Director
- Bryan RobertsDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.4MraisedJan 2023 · 4 investors · BiotechnologyRule 506(b)
▶$4.4MraisedJan 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Ron McGrathExecutive Officer
- Kristala L. Jones PratherDirector
- Sri KosarajuExecutive Officer, Director
- Roger WyseDirector
- Bryan RobertsDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.8MraisedJan 2023 · 5 investors · BiotechnologyRule 506(b)
▶$27.8MraisedJan 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron McGrathExecutive Officer
- Roger WyseDirector
- Sri KosarajuExecutive Officer, Director
- Kristala L. Jones PratherDirector
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Bryan RobertsDirector
- Offering amount
- $27.8M
- Amount sold
- $27.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150MraisedApr 2021 · 32 investors · BiotechnologyRule 506(b)
▶$150MraisedApr 2021 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GraigeExecutive Officer
- John R. StuelpnagelDirector
- Ron McGrathExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Roger WyseDirector
- Dianna L. DeVoreExecutive Officer
- Bryan RobertsDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedNov 2020 · 6 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dianna L. DeVoreExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Ron McGrathExecutive Officer
- Michael GraigeExecutive Officer
- Roger WyseDirector
- John R. StuelpnagelDirector
- Bryan RobertsDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$8.1MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John R. StuelpnagelDirector
- Roger WyseDirector
- Michael GraigeExecutive Officer
- Ron McGrathExecutive Officer
- Dianna L. DeVoreExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Bryan RobertsDirector
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.1MraisedDec 2019 · 12 investors · BiotechnologyRule 506(b)
▶$92.1MraisedDec 2019 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron McGrathExecutive Officer
- Jason GammackExecutive Officer
- Kevin D. NessExecutive Officer, Director
- Michael GraigeExecutive Officer
- Dianna DeVoreExecutive Officer
- Tanya LipscombPromoter
- Bryan RobertsDirector
- John R. StuelpnagelDirector
- Roger WyseDirector
- Andrew D. GarstPromoter
- Ryan T. GillPromoter
- Offering amount
- $125M
- Amount sold
- $92.1M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$50MraisedApr 2019 · 14 investors · BiotechnologyRule 506(b)
▶$50MraisedApr 2019 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D. NessExecutive Officer, Director
- Dianna DeVoreExecutive Officer
- Bryan RobertsDirector
- John R. StuelpnagelDirector
- Jason GammackExecutive Officer
- Andrew D. GarstPromoter
- Ryan T. GillPromoter
- Tanya LipscombPromoter
- Michael GraigeExecutive Officer
- Roger WyseDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Scribe Therapeutics10 shared keywordsScribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Predictabiosciences8 shared keywordsPredicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.
Transcripta Bio8 shared keywordsTranscripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution. Its drug discovery platform draws on single-cell genomics and AI for biology.
Manus Bio6 shared keywordsManus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing. Its products include sweeteners and flavor/fragrance ingredients supplied to food and consumer goods companies such as Tate & Lyle and Givaudan.
Septerna5 shared keywordsSepterna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline focuses on endocrinology, immunology and inflammation, and metabolic diseases for patients with unmet medical needs.
Companies competing with Inscripta for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Inscripta's investors?
- Inscripta's investors include Foresite Capital, iGlobe Partners, Korys, Oak HC/FT, OMX Ventures, Paladin Capital Group, Spruce Capital Partners, Venrock and 2 more.
- How much funding has Inscripta raised?
- Inscripta has disclosed $473.9M raised across 14 rounds.
- Where is Inscripta headquartered?
- Inscripta is headquartered in Boulder, US.